Creathor in €10m series-B for Acousia

LBBW Ventures, Bregua Corporation and existing backers Boehringer Ingelheim Venture Fund (BIVF) and Kreditanstalt für Wiederaufbau (KfW) also took part in the financing.

The fresh capital will be used to enhance the company's most advanced drug candidate, Acou085, to the clinical stage.

Previous funding
BIVF, KfW and Axxam invested in a €2.5m series-A for Acousia in December 2016. It had previously received seed funding from BIVF.

Company
Acousia was founded in 2012 and is headquartered in Tübingen, Germany. The company has established a portfolio of cures for hearing impairment, which it says affects 10-15% of Europeans. The predominant cause is the loss of sensor hair cells in the inner ear and Acousia develops drugs for sensory hair cell protection and restoration.

People
Creathor Ventures – Karlheinz Schmelig (managing partner).
Acousia Therapeutics – Christoph Antz (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Germany
• Venture